Navigation Links
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Date:9/14/2009

R compared to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)**, and a 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)**.

In March 2009 at the American College of Cardiology annual meeting, Abbott presented long-term data from the SPIRIT II clinical trial of 300 patients, which showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. XIENCE V demonstrated a 57 percent reduction in the risk of MACE compared to TAXUS at three years (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)**.

In addition, there was no occurrence of stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)** in the SPIRIT II trial. The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

In May 2009 at EuroPCR, Abbott presented one-year data from the SPIRIT V (five) international, single-arm study, which evaluated XIENCE V in 2,663 patients - including more than 60 patients enrolled at two sites in China. XIENCE V demonstrated low rates of repeat procedure (target lesion revascularization or TLR), stent thrombosis and MACE in a diverse, "real world" population of patients and lesion types, including patients with diabetes, patients with multi-vessel disease and patients with highly complex lesions. In the SPIRIT V study, XIENCE V demonstrated a very low 1.8 percent rate of TLR, a 0.7 percent rate of definite/probable stent thrombosis and a 5.1 percent rate
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
2. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
3. Abbott HIV Test Demonstrates Earlier Disease Detection
4. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Abbott Named One of the Top 10 Companies for Scientists
7. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
8. Abbott to Present at Barclays Global Healthcare Conference
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Abbott Announces 11 Percent Increase in Quarterly Dividend
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... DIEGO , May 16, 2013  The registration ... of Bioscience Financial Officers (ABFO) 2013 National Conference, the ... be held May 28-31 at the Hilton San Diego ... touches on this year,s conference and want to make ... to attend," said Brandi Roberts , ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 As the weather ... showcase their favorite Spring looks. While most make a statement ... Unfortunately, many women find the warmer weather mixes makeup and ... cope with the onset of acne during warmer months, ... female acne treatment users the best ways to deter breakouts. ...
(Date:5/16/2013)... May 16, 2013 Reportlinker.com ... report is available in its catalogue: ... Competitor Analysis: Therapeutic Proteins – Biosimilars, ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ... The new Competitive Intelligence Report ...
(Date:5/16/2013)... VA (PRWEB) May 16, 2013 BioInformatics ... Primary Cells & Stem Cell-Derived Cells: Current and Future ... the number of suppliers in the primary cells market ... what cell types are used most often, how satisfied ... the market size and anticipated growth rate. , ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Spain, September 29, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... (Nasdaq: VRNM ), a pioneer in ... solutions, today announced that it will now market ... enzyme for the saccharification of liquefied starch in ... L-E5 enzyme has demonstrated high ethanol yields at ...
... 29 Susquehanna Health, a three-hospital health ... an integrated perioperative information management system provided ... solution will integrate seamlessly into the hospitals, ... System enhance patient safety and drive business ...
Cached Biology Technology:ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 2ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 3ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 4ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 5ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 6ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy 7Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production 2Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production 3Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 2Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 3Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 4
(Date:5/17/2013)... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ... sequestration is "having a substantial impact on the scientific ...
(Date:5/16/2013)... to Research Careers) Program has announced the travel ... Annual Meeting in San Francisco, CA from June ... the entry of students, postdoctorates and scientists from ... science community and to encourage the participation of ... , Awards are given to poster/platform presenters and ...
(Date:5/16/2013)... have used ancient shorelines to predict the stability of today,s ... high shoreline from three million years ago, for example ... thought to be evidence of a high sea level due ... led many scientists to think that if the world,s largest ... just the same in our modern, progressively warming world. ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2
... 29 July issue of the international journal Nature ... as "phytoplankton" have been declining globally over the 20th century. ... sustains diverse assemblages of species ranging from tiny zooplankton to ... Boyce, "Phytoplankton is the fuel on which marine ecosystems run. ...
... to entomology, Thomas Miller , a professor of ... elected a fellow of the prestigious Entomological Society of ... professional and scientific needs of entomologists and people in related ... others were elected to this honor. They will be ...
... eat anything they want and never gain a pound, while ... foods? You may be seeing things correctly after all. ... Genetics ( http://www.genetics.org ), this may have a ... interacting with diet, rather than diet alone, are the main ...
Cached Biology News:New study reveals decline of marine phytoplankton over the past century 2UC Riverside faculty member joins elite group of entomologists 2Why fad diets work well for some, but not others 2
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
... HERAfreeze ultra low temperature freezers offer ... safe storage of biological samples with ... five separate inner doors ensure excellent ... costs. ,Application oriented accessories simplify ...
...
...
Biology Products: